IsoRay Q1 revenue up 7% YoY in prostate cancer cases.

sábado, 6 de diciembre de 2025, 3:07 am ET1 min de lectura
CATX--

• IsoRay reports 7% revenue growth in prostate cancer cases QoQ • Revenue increase attributed to new healthcare reforms and aging baby boomers • Prostate revenue up from Q1 2013 and October 2014 • Company sees potential for consistent revenue increases in prostate treatment

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios